hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06361394, orgStudyIdInfo id: CORPFIN0021, briefTitle: The Impacts of Mindfulness on Psychological Wellbeing Among Nursing Students, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2024-07-25, completionDateStruct date: 2025-08-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Chang Gung University of Science and Technology, class: OTHER, descriptionModule briefSummary: The aims of this study are to develop a mindfulness-based course for nursing students. As well as, to verify the effects on psychological well-being (mindfulness, stress, and anxiety) and nursing professional related competences (empathy, clinical practicum stress, nursing competency) among nursing students., conditionsModule conditions: Students, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The experimental group will enroll in the elective course named "Mindfulness and Happiness," which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: mindfulness course, outcomesModule primaryOutcomes measure: perceived stress at baseline, primaryOutcomes measure: perceived stress at T0, primaryOutcomes measure: perceived stress at T1, primaryOutcomes measure: perceived stress at T2, primaryOutcomes measure: anxiety disorder at baseline, primaryOutcomes measure: anxiety disorder at T0, primaryOutcomes measure: anxiety disorder at T1, primaryOutcomes measure: anxiety disorder at T2, primaryOutcomes measure: mindful attention awareness at baseline, primaryOutcomes measure: mindful attention awareness at T0, primaryOutcomes measure: mindful attention awareness at T1, primaryOutcomes measure: mindful attention awareness at T2, primaryOutcomes measure: empathy at baseline, primaryOutcomes measure: empathy at at T0, primaryOutcomes measure: empathy at at T1, primaryOutcomes measure: empathy at at T2, primaryOutcomes measure: practicum stress at T1, primaryOutcomes measure: practicum stress at T2, primaryOutcomes measure: Nursing Competence at T1, primaryOutcomes measure: Nursing Competence at T2, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ya-Chu Hsiao, status: RECRUITING, city: Taoyuan City, state: N/A = Not Applicable, zip: 333 03, country: Taiwan, contacts name: ya-chu hsiao, EdD, role: CONTACT, phone: +886939740890, email: yjshiao@mail.cgust.edu.tw, geoPoint lat: 24.95233, lon: 121.20193, hasResults: False
protocolSection identificationModule nctId: NCT06361368, orgStudyIdInfo id: NYCU112174AF, briefTitle: Efficacy Assessment of Probiotics in Improving Sleep Indices, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: National Yang Ming University, class: OTHER, collaborators name: Bened Biomedical Co., Ltd., descriptionModule briefSummary: To determine whether PS150 (1) reduces insomnia symptoms, (2) improves sleep quality, (3) adjusts autonomic nervous system functioning, (4) reduces the severity of anxiety and depressive symptoms, and (5) adjusts microbiome and endocrine functions., conditionsModule conditions: Insomnia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: PS150, interventions name: Placebo, outcomesModule primaryOutcomes measure: Polysomnography (PSG), secondaryOutcomes measure: Pittsburgh Sleep Quality Index (PSQI), secondaryOutcomes measure: Insomnia Severity Index (ISI), secondaryOutcomes measure: Beck Depression Inventory-Second Edition (BDI-II), secondaryOutcomes measure: Beck Anxiety Inventory (BAI), secondaryOutcomes measure: VAS-Sleep, secondaryOutcomes measure: Epworth Sleepiness Scale (ESS), secondaryOutcomes measure: Standford Sleepiness Scale (SSS), secondaryOutcomes measure: Visual Analogue Scale for gastrointestinal symptoms (VAS-GI), secondaryOutcomes measure: Saliva Melatonin, secondaryOutcomes measure: Saliva Cortisol, secondaryOutcomes measure: Saliva IL-6, secondaryOutcomes measure: Saliva Total Antioxidant Capacity (TAC), secondaryOutcomes measure: Saliva Serotonin, secondaryOutcomes measure: Saliva GABA, secondaryOutcomes measure: Saliva Orexin, secondaryOutcomes measure: Urine 6-sulfatoxymelatonin, secondaryOutcomes measure: Urine Norepinephrine, secondaryOutcomes measure: Actigraphy, secondaryOutcomes measure: Sleep Diary, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Institute of Brain Science National Yang Ming Chiao Tung University, city: Taipei, zip: 112304, country: Taiwan, contacts name: Yu En Kuo, Master, role: CONTACT, phone: +886 975231262, email: iankuo1106@gmail.com, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06361355, orgStudyIdInfo id: CMAB807-I-002, briefTitle: Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-02, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Taizhou Mabtech Pharmaceutical Co.,Ltd, class: INDUSTRY, descriptionModule briefSummary: This is a randomized, double-blinded, parallel-controlled Phase I study of CMAB807 administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807 Post-change in Manufacturing Site, versus Prolia #Denosumab# in healthy male subjects after a single dose, conditionsModule conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Biological: Post-change CMAB807, Prolia, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 132, type: ESTIMATED, armsInterventionsModule interventions name: Post-change CMAB807, interventions name: Prolia, outcomesModule primaryOutcomes measure: Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time, primaryOutcomes measure: Maximum Concentration of Denosumab, secondaryOutcomes measure: Time to Maximum Concentration of Denosumab, secondaryOutcomes measure: Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 3000 Hours, secondaryOutcomes measure: Half-time, secondaryOutcomes measure: Clearance Rate, secondaryOutcomes measure: Apparent Volume, secondaryOutcomes measure: Serum type 1 C-telopeptide (CTX1), secondaryOutcomes measure: anti-drug antibodies(ADA), secondaryOutcomes measure: Neutralization antibodies(Nab), otherOutcomes measure: Percentage and Severity of Participants with Adverse Events, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: The Second Hospital of Anhui Medical University, status: RECRUITING, city: Hefei, state: Anhui, country: China, contacts name: Hu Wei, Doctor, role: CONTACT, phone: 0551-65997164, email: hwgcp@ayefy.com, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06361342, orgStudyIdInfo id: 23-003633, briefTitle: Smartphones Aggravating Anxiety Symptoms, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The goal of this study is to assess if excessive use of smartphone apps of social media can impact a person's mental health. The study is aimed at improving the usage of smartphones which might help improve the mental health of patients. The goal is not to discourage the use of smartphones but instead to utilize smartphones in a way that they do not impact lives., conditionsModule conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: General decrease in smartphone use, interventions name: Avoiding Social Media Apps, outcomesModule primaryOutcomes measure: Change in anxiety, secondaryOutcomes measure: Change in depression, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic Minnesota, city: Rochester, state: Minnesota, zip: 55905, country: United States, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06361329, orgStudyIdInfo id: 20240030C, briefTitle: Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: First Affiliated Hospital of Zhejiang University, class: OTHER, descriptionModule briefSummary: ETP-ALL is a subtype of T-cell acute lymphoblastic leukemia (T-ALL) with poor outcomes and prognosis. Effective induction therapy is crucial in improving the treatment effect. Based on our laboratory research and clinical practice, the venetoclax plus HAG regimen shows promising efficacy in treating ETP-ALL. Therefore, we plan to conduct a prospective, multicenter Phase III clinical study to evaluate the efficacy of the venetoclax plus HAG regimen in treating newly diagnosed ETP-ALL patients., conditionsModule conditions: ETP-ALL, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 81, type: ESTIMATED, armsInterventionsModule interventions name: Homoharringtonine, interventions name: venetoclax, interventions name: Cytarabine, interventions name: G-CSF, interventions name: Vindesine, interventions name: Daunorubicin, interventions name: cyclophosphamide, interventions name: Dexamethasone, interventions name: L-ASP, outcomesModule primaryOutcomes measure: 1-year EFS, secondaryOutcomes measure: CR/CRi, secondaryOutcomes measure: OS, secondaryOutcomes measure: MRD, secondaryOutcomes measure: Safety of induction therapy, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital, College of Medicine, Zhejiang University, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310003, country: China, contacts name: Jie Jin, PhD&MD, role: CONTACT, phone: 13705716779, email: jiej0503@163.com, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06361316, orgStudyIdInfo id: CSPC-DEY-PC-JS01, briefTitle: Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2025-03-25, completionDateStruct date: 2028-07-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Kuirong Jiang, class: OTHER, collaborators name: CSPC Ouyi Pharmaceutical Co., Ltd., descriptionModule briefSummary: The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer., conditionsModule conditions: Pancreatic Cancer, conditions: Adjuvant Therapy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 53, type: ESTIMATED, armsInterventionsModule interventions name: Irinotecan liposome injection, outcomesModule primaryOutcomes measure: Disease Free Survival, DFS, secondaryOutcomes measure: Adverse events (aes) were determined and graded according to NCI-CTCAE version 5.0, and evaluated by the overall incidence of AE, the incidence of AE grade 3 or above, and the incidence of SAE, secondaryOutcomes measure: Overall Survival, OS, secondaryOutcomes measure: Quality of life, QOL, secondaryOutcomes measure: The results were presented in terms of the proportion of patients who completed 6 months of chemotherapy, secondaryOutcomes measure: he results were presented in terms of the proportion of patients who were replaced with 5-FU/LV due to Tegafur intolerance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: FirstNanjingMU, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 025, country: China, contacts name: KuiRong Jiang, archiater, role: CONTACT, phone: 15312995688, email: Jiangkuirong@163.com, contacts name: Min Tu, associate doctor, role: SUB_INVESTIGATOR, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06361303, orgStudyIdInfo id: PS230001, secondaryIdInfos id: PS230001 / PSS001, type: OTHER, domain: US FDA, briefTitle: The Happiest Baby, Inc. SNOO Postmarket Surveillance Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-29, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Happiest Baby, Inc., class: INDUSTRY, descriptionModule briefSummary: This postmarket surveillance study will evaluate the safety of the SNOO Smart Sleeper Bassinet when used for infants who are at high risk for Sudden Unexpected Infant Death (SUID). This study will survey 1000 caregivers of high-risk infants to examine the frequency of death or serious injury occurring in the SNOO Bassinet., conditionsModule conditions: Infant Death, conditions: Serious Injury, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: SNOO Bassinet, outcomesModule primaryOutcomes measure: Serious Injury, primaryOutcomes measure: Infant death, secondaryOutcomes measure: Infant age during SNOO use, secondaryOutcomes measure: Degree of SNOO use, secondaryOutcomes measure: Weaning rationale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Happiest Baby, Inc., status: RECRUITING, city: Los Angeles, state: California, zip: 90064, country: United States, contacts name: Christopher Laine, PhD, role: CONTACT, phone: 310-476-4440, email: christopher@happiestbaby.com, contacts name: Sarah Chang, MPH, role: CONTACT, phone: 310-476-4440, email: schang@happiestbaby.com, contacts name: Christopher Laine, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06361290, orgStudyIdInfo id: APHP231703, briefTitle: Diaphyseal Reconstruction of Malignant Tumors in Children, acronym: RDTM, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: Primary malignant bone tumors represent 5% of malignant tumors in children, 90% of which are osteosarcomas or Ewing sarcomas.The objective of oncological resection is local control of the disease. Excision of the entire tumor should make it possible to maintain good function of the limb, minimizing morbidity, and promoting acceptance by the patient.Biological reconstructions offer the best long-term functional results. Several possibilities are then available: the Induced Membrane technique, the Vascularized Fibula and Vascularized Fibula associated with an Allograft.Until today, no reconstruction technique in children has proven its superiority over another and no decision-making algorithm for therapeutic care has been determined based on the importance of the bone resection and the affected segment in diaphyseal tumor reconstruction surgery of the lower limb.The aim of the present research is to compare the three techniques concerning the consolidation aspect, the reoperation rates, the rates of bone complications, septic, and the functional results by the study of the medical files of approximately 90 patients operated between 1986 and 2017., conditionsModule conditions: Childhood Malignant Tumors of Lower Limbs, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Data collection from hospital medical records, outcomesModule primaryOutcomes measure: Duration of bone consolidation period, secondaryOutcomes measure: Rate of surgical re-intervention, secondaryOutcomes measure: Short- and long-term complication rates, secondaryOutcomes measure: Long-term functional results, secondaryOutcomes measure: Relationship between radiotherapy and biological reconstruction result, eligibilityModule sex: ALL, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Hôpital Armand-Trousseau, city: Paris, zip: 75012, country: France, contacts name: Franck Fitoussi, MD-PhD, role: CONTACT, phone: 679693634, phoneExt: +33, email: franck.fitoussi@trs.aphp.fr, geoPoint lat: 48.85341, lon: 2.3488, locations facility: Hôpital Necker-Enfants Malades, city: Paris, zip: 75015, country: France, contacts name: Edouard Haumont, MD, role: CONTACT, phone: 486587192, phoneExt: +32, email: edouard.haumont@.aphp.fr, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06361277, orgStudyIdInfo id: JW22104, briefTitle: To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-11-03, primaryCompletionDateStruct date: 2023-11-20, completionDateStruct date: 2023-11-27, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: JW Pharmaceutical, class: INDUSTRY, descriptionModule briefSummary: The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0202 and C2202 and co-administration of C2205 and JW0201 in healthy volunteers under fasting conditions, conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 56, type: ACTUAL, armsInterventionsModule interventions name: Reference Drug or Test Drug, outcomesModule primaryOutcomes measure: AUCt, primaryOutcomes measure: Cmax, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Clinical Trial Center, Jeonbuk National University Hospital, city: Jeonju, country: Korea, Republic of, geoPoint lat: 35.82194, lon: 127.14889, hasResults: False
protocolSection identificationModule nctId: NCT06361264, orgStudyIdInfo id: Karanahan, briefTitle: Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-11-01, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: KARANAHAN, class: OTHER, descriptionModule briefSummary: The goal of this study is to evaluate the safety and clinical efficacy of personalized chemotherapy with low doses of cyclophosphamide administered taking into account the reparative cycle of tumor cells in participants with breast cancer (stage IV or disease progression). The main question it aims to answer is: Does personalized chemotherapy of breast cancer with low doses of cyclophosphamide, taking into account the reparative cycle of tumor cells, lead to a significant reduction in tumor size and improvement in the visual status of controlled tumor foci relative to their initial state? During the preparatory stage, a tumor sample from participant is harvested intraoperatively. The primary culture is obtained from this tumor tissue sample. Repair cycle time is estimated, and the day when tumor cells are synchronized at the cell cycle G2/M phase is identified. The schedule of administering cyclophosphamide and DNAmix complex composite preparation is calculated according to the resulting time points. According to the elaborated regimen, the participant receives 4 intravenous cyclophosphamide injections at the dose of 300 mg/m2 in combination with 4 injections of 1-12 mg of DNAmix administered into prominent tumor nidi and lymph depots. The participant receives from 2 to 6 courses of therapy. The interval between courses is 21 days., conditionsModule conditions: Stage IV Breast Cancer, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Karanahan, outcomesModule primaryOutcomes measure: The size of tumor foci, secondaryOutcomes measure: The quality of life score, secondaryOutcomes measure: The immunomodulatory effect, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Karanahan Llc, status: RECRUITING, city: Novosibirsk, state: Novosibirsk Region, zip: 630090, country: Russian Federation, contacts name: Anastasia Proskurina, role: CONTACT, email: labmolbiol@mail.ru, contacts name: Sergey Sidorov, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 55.0415, lon: 82.9346, hasResults: False